logo

For the Inventor, By the Inventor

Bethesda, MD, United States of America

Ching-Juh Lai

USPTO Granted Patents = 29 


 

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 166(Granted Patents)


Location History:

  • Bethesda, MA (US) (2017 - 2022)
  • Bethesda, MD (US) (2001 - 2023)

Company Filing History:

goldMedal29 out of 3,539 
 
The United States of America, As Represented by the Secretary, Department of Health and Human Services
 patents

Years Active: 2001-2025

Loading Chart...
Loading Chart...
Loading Chart...
29 patents (USPTO):Explore Patents
1. 12203100 - Development of dengue virus vaccine components (2025-01-21),
2. 11753627 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 (2023-09-12),
3. 11746335 - Development of dengue virus vaccine components (2023-09-05),
4. 11332722 - Development of dengue virus vaccine components (2022-05-17),
5. 11318196 - Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein (2022-05-03),
6. 10837003 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 (2020-11-17),
7. 10724007 - Development of dengue virus vaccine components (2020-07-28),
8. 10500264 - Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses (2019-12-10),
9. 10160957 - Development of dengue virus vaccine components (2018-12-25),
10. RE46641 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 (2017-12-18),
11. RE46631 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 (2017-12-11),
12. 9783787 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 (2017-10-10),
13. 9783596 - Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use (2017-10-10),
14. 9707287 - Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein (2017-07-18),
15. RE46042 - Development of dengue virus vaccine components (2016-06-27),

Title: The Innovative Journey of Ching-Juh Lai

Introduction: Ching-Juh Lai, a pioneering inventor based in Bethesda, MD, has made significant contributions to the field of technology with her groundbreaking innovations.

Latest Patents: Ching-Juh Lai holds several patents in the areas of biotechnology and medical devices, showcasing her commitment to advancing healthcare through technological solutions.

Career Highlights: With a background in bioengineering, Ching-Juh Lai has led successful research projects that have resulted in the development of cutting-edge medical devices aimed at improving patient outcomes.

Collaborations: Throughout her career, Ching-Juh Lai has collaborated with leading research institutions and medical professionals to bring her inventions from concept to reality, demonstrating her ability to work effectively in multidisciplinary teams.

Conclusion: Ching-Juh Lai's dedication to innovation and her passion for improving healthcare have solidified her reputation as a respected inventor in the field of biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…